



## PA Submission Information

The guidance outlined below may be helpful as you fill out and submit PAs for your patients.

The following information may be needed for the PA:

| CLINICAL DIAGNOSIS   | PREVIOUS THERAPY WITHIN THE LAST 12 MONTHS   |
|--|--|
| <p>Please see ICD-10 codes (<i>available on page 2</i>)</p> <p><b>Adult patients (aged ≥18 years):</b> List all of the patient's diagnoses for the product being requested</p> | <p>List all previous schizophrenia or bipolar depression products prescribed for the patient over the last 12 months</p> |

ICD-10=International Classification of Diseases, Tenth Revision; PA=prior authorization.

CAPLYTA is indicated in adults for the treatment of schizophrenia and depressive episodes associated with bipolar I or II disorder (bipolar depression), as monotherapy and as adjunctive therapy with lithium or valproate.

### Important Safety Information

#### Boxed Warnings:

- **Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. CAPLYTA is not approved for the treatment of patients with dementia-related psychosis.**
- **Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adults in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors. The safety and effectiveness of CAPLYTA have not been established in pediatric patients.**

**Contraindications:** CAPLYTA is contraindicated in patients with known hypersensitivity to lumateperone or any components of CAPLYTA. Reactions have included pruritus, rash (e.g., allergic dermatitis, papular rash, and generalized rash), and urticaria.

**Warnings & Precautions:** Antipsychotic drugs have been reported to cause:

- **Cerebrovascular Adverse Reactions in Elderly Patients with Dementia-Related Psychosis**, including stroke and transient ischemic attack. See Boxed Warning above.
- **Neuroleptic Malignant Syndrome**, which is a potentially fatal reaction. Signs and symptoms include hyperpyrexia, muscle rigidity, delirium, autonomic instability, elevated creatinine phosphokinase, myoglobinuria (and/or rhabdomyolysis), and acute renal failure. Manage with immediate discontinuation of CAPLYTA and provide intensive symptomatic treatment and monitoring.
- **Tardive Dyskinesia (TD)**, a syndrome of potentially irreversible, dyskinetic, and involuntary movements which may increase as the duration of treatment and total cumulative dose increases. The syndrome can develop after a relatively brief treatment period, even at low doses, or after treatment discontinuation. Given these considerations, CAPLYTA should be prescribed in a manner most likely to reduce the risk of TD. Discontinue CAPLYTA if clinically appropriate.
- **Metabolic Changes**, including hyperglycemia, diabetes mellitus, dyslipidemia, and weight gain. Hyperglycemia, in some cases extreme and associated with ketoacidosis, hyperosmolar coma or death, has been reported in patients treated with antipsychotics. Measure weight and assess fasting plasma glucose and lipids when initiating CAPLYTA and monitor periodically during long-term treatment.
- **Leukopenia, Neutropenia, and Agranulocytosis (including fatal cases)**. Perform complete blood counts in patients with pre-existing low white blood cell count (WBC) or history of leukopenia or neutropenia. Discontinue CAPLYTA if clinically significant decline in WBC occurs in absence of other causative factors.
- **Orthostatic Hypotension and Syncope**. Monitor heart rate and blood pressure and warn patients with known cardiovascular or cerebrovascular disease. Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension.
- **Falls**. CAPLYTA may cause somnolence, postural hypotension, and motor and/or sensory instability, which may lead to falls and, consequently, fractures and other injuries. Assess patients for risk when using CAPLYTA.

Please see additional [Important Safety Information](#) on next page.

# How to Resolve Common PA Requirements for CAPLYTA® (lumateperone)

| TOP REASONS  | HOW TO RESOLVE  |
|--|---|
| The patient must try/fail all preferred alternatives                 | Some plans require patients to try one or more generic options before covering CAPLYTA. Please list all previous therapy agents as appropriate. |
| The patient's diagnosis is not consistent with the drug's indication | Below are ICD-10 codes that can be used with CAPLYTA*   |

| EXAMPLES OF ICD-10 CODES FOR BIPOLAR DEPRESSION (I & II) AND SCHIZOPHRENIA <sup>1*</sup> |   |               |                                |
|--|---|---------------|--------------------------------|
| <b>F31.30</b>  | Bipolar disorder, current episode depressed, mild or moderate severity, unspecified | <b>F20.0</b>  | Paranoid schizophrenia         |
| <b>F31.31</b>  | Bipolar disorder, current episode depressed, mild                                   | <b>F20.1</b>  | Disorganized schizophrenia     |
| <b>F31.32</b>  | Bipolar disorder, current episode depressed, moderate                               | <b>F20.2</b>  | Catatonic schizophrenia        |
| <b>F31.4</b>   | Bipolar disorder, current episode depressed, severe, without psychotic features     | <b>F20.3</b>  | Undifferentiated schizophrenia |
| <b>F31.5</b>   | Bipolar disorder, current episode depressed, severe, with psychotic features        | <b>F20.5</b>  | Residual schizophrenia         |
| <b>F31.81</b>  | Bipolar II disorder   | <b>F20.89</b> | Other schizophrenia            |
| <b>F31.89</b>  | Other bipolar disorder  | <b>F20.9</b>  | Schizophrenia, unspecified     |
| <b>F31.9</b>   | Bipolar disorder, unspecified   |               |                                |

\*Disclaimer: These codes are presented for informational purposes only. They represent no statement, promise, or guarantee by Intra-Cellular Therapies, Inc., concerning coverage and/or levels of reimbursement, payment, or charge and are not intended to increase or maximize reimbursement by any payer. It is the responsibility of the healthcare provider to determine the appropriate code(s) for service provided to his or her patient. Laws, regulations, and policies concerning reimbursement are complex and updated frequently. Although we have made an effort to be current as of July 2023, the information may not be current or comprehensive when you view it. Please consult the applicable payer organization with regard to local or actual coverage, reimbursement policies, and determination processes.

## Important Safety Information (continued)

**Warnings & Precautions:** Antipsychotic drugs have been reported to cause:

- **Seizures.** Use CAPLYTA cautiously in patients with a history of seizures or with conditions that lower seizure threshold.
- **Potential for Cognitive and Motor Impairment.** Advise patients to use caution when operating machinery or motor vehicles until they know how CAPLYTA affects them.
- **Body Temperature Dysregulation.** Use CAPLYTA with caution in patients who may experience conditions that may increase core body temperature such as strenuous exercise, extreme heat, dehydration, or concomitant anticholinergics.
- **Dysphagia.** Use CAPLYTA with caution in patients at risk for aspiration.

**Drug Interactions:** Avoid concomitant use with CYP3A4 inducers. Reduce dose for concomitant use with strong CYP3A4 inhibitors (10.5 mg) or moderate CYP3A4 inhibitors (21 mg).

**Special Populations:** Neonates exposed to antipsychotic drugs during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery. Reduce dose for patients with moderate or severe hepatic impairment (21 mg).

**Adverse Reactions:** The most common adverse reactions in clinical trials with CAPLYTA vs placebo were:

- Schizophrenia: somnolence/sedation (24% vs 10%) and dry mouth (6% vs 2%).
- Bipolar Depression (Monotherapy, Adjunctive therapy): somnolence/sedation (13% vs 3%, 13% vs 3%), dizziness (8% vs 4%, 11% vs 2%), nausea (8% vs 3%, 9% vs 4%), and dry mouth (5% vs 1%, 5% vs 1%).

CAPLYTA is available in 10.5 mg, 21 mg, and 42 mg capsules.

Please see full [Prescribing Information](#), including Boxed Warnings.

**Reference: 1.** Centers for Disease Control and Prevention. Tabular list of diseases: F20.0. Centers for Disease Control and Prevention website. Accessed July 18, 2023. <https://icd10cmtool.cdc.gov/?fy=FY2022&query=f20.0>

CAPLYTA is a registered trademark of Intra-Cellular Therapies, Inc.

© 2023 Intra-Cellular Therapies, Inc. All rights reserved. US-CAP-2300419 08/23